Loading company
Aktis Oncology, Inc.
AKTS · Nasdaq · ·
$19.72+2.2%Sep 29 close
- 1M
- -23.5%
- 6M
- +19.2%
- 1Y
- +52,897.3%
- 5Y
- +84.3%
AKTS · Nasdaq · ·
$19.72+2.2%Sep 29 close
From the company’s own 8-K filing.
Aktis Oncology, Inc. has no earnings call transcript available.
“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anticancer activity through high tumor penetration coupled with internalization and retention in cancer cells, while rapidly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, and its patient-first end-to-end clinical supply chain built for resiliency and scalability, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aktis Oncology, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.